Recent Updates
Recently added Catalysts
NMTC Positive Sentiment Score: 75/100

NeuroOne to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

Key Takeaway: NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced its participation in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference on March 19, 2025. CEO Dave Rosa will host a virtual presentation and engage in one-on-one meetings during the event. The company focuses on developing minimally invasive solutions for various neurological disorders, including epilepsy and Parkinson's disease, with an emphasis on improving patient care and reducing costs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prominent healthcare conference shows industry engagement.
  • Focus on innovative medical technology aimed at neurological disorders.
  • Potential to improve patient outcomes with advanced solutions.
  • CEO participation highlights leadership and company visibility.

Full Press Release Details

EDEN PRAIRIE, Minn., March 05, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced that it will participate in the upcoming Oppenheimer 35th Annual Healthcare Conference MedTech & Services Conference on Wednesday, March 19, 2025.
NeuroOne CEO Dave Rosa will host a virtual corporate presentation at 9:20 a.m. eastern time on Wednesday, March 19, 2025, followed by one-on-one meetings, which can be requested through Oppenheimer. To join live or view a replay of the webcast, please visit this link or the events page on NeuroOne’s investors relations website.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit www.nmtc1.com.
MZ Group – MZ North America

Tags

NeuroOne Medical Technologies
Healthcare MedTech & Services

Frequently Asked Questions

When is NeuroOne participating in the healthcare conference?

NeuroOne will participate on March 19, 2025.

Who will host the NeuroOne corporate presentation?

CEO Dave Rosa will host the presentation.

What conditions does NeuroOne aim to address?

NeuroOne focuses on neurological disorders like epilepsy and Parkinson’s disease.

Can I watch the NeuroOne presentation live?

Yes, you can join live or view a replay on their website.

What technologies is NeuroOne developing?

They are developing hi-definition EEG solutions and brain stimulation technologies.

Last updated: Mar 5, 2025